Ohnoshi T, Hiraki S, Kawahara S, Yamashita H, Yonei T, Ishii J, Egawa T, Kozuka A, Hiraki Y, Kimura I
Jpn J Clin Oncol. 1986 Sep;16(3):271-7.
In order to assess the effectiveness of chest irradiation in addition to intensive chemotherapy in limited stage small cell lung cancer, 50 patients were randomized to receive either chemotherapy alone or chemotherapy plus chest irradiation, between April 1981 and October 1985. The chemotherapy regimen consisted of a four-drug combination of cyclophosphamide, vincristine, methotrexate, and procarbazine, and a three-drug combination of etoposide, adriamycin, and nimustine, given alternately every 8 weeks. One group of 26 patients received the chemotherapy alone, and another group of 24 patients received chest irradiation with 40 Gy between cycles 1 and 2 of the chemotherapy. Complete response rates were quite similar in the two groups; 50% for those receiving chemotherapy alone, and 59% for those receiving chemotherapy plus chest irradiation. There were no significant differences in median survival (15 months versus 12 months) and in long-term survival rates between the two groups with a median follow-up period of 26 months. The combined modality treatment was more toxic than chemotherapy alone; two patients receiving such treatment died of radiation pneumonitis. It is concluded that chest irradiation combined with chemotherapy does not affect the response rate, survival, or pattern of recurrence in patients with limited stage small cell lung cancer.
为了评估胸部放疗联合强化化疗对局限期小细胞肺癌的疗效，1981年4月至1985年10月期间，50例患者被随机分为两组，分别接受单纯化疗或化疗加胸部放疗。化疗方案包括环磷酰胺、长春新碱、甲氨蝶呤和丙卡巴肼的四联组合，以及依托泊苷、阿霉素和尼莫司汀的三联组合，每8周交替使用。一组26例患者接受单纯化疗，另一组24例患者在化疗的第1和第2周期之间接受40 Gy的胸部放疗。两组的完全缓解率相当相似；单纯化疗组为50%，化疗加胸部放疗组为59%。两组的中位生存期（15个月对12个月）和长期生存率无显著差异，中位随访期为26个月。联合治疗比单纯化疗毒性更大；两名接受这种治疗的患者死于放射性肺炎。结论是，胸部放疗联合化疗对局限期小细胞肺癌患者的缓解率、生存率或复发模式没有影响。
